Knowing your genetic peptide response saves money by directing you toward the most effective medication for your biology from day one
The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability resulting in approximately three times greater potency than IGF-1, with a significantly longer half-life of about 2030 hours relative to IGF-1s half-life of about 1215 hours
When these exposures are reported to poison control, referral to a healthcare facility and a recommended observation period are based on symptom severity
Michelet F, Gueguen R, Leroy P, et al
Wegovy frequently causes nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during dose escalation